EN
icon
CN
CN | EN
Who We Are
EpimAb Biotherapeutics Inc is a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies. Utilizing our broad range of in-house research and technology capabilities, including the proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platforms, EpimAb is generating and globally advancing a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients.
undefined
Promising Pipeline Derived From In-House Research
Preclinical and clinical assets address global unmet medical needs
Sustainable first-/best-in-class pipeline with 3 candidates in the clinic
Novel and Proprietary Bispecific Antibody Technology Platform
World-class innovative BsAb platform with strong IP
Rapid and proven bispecific antibody development process that is comparable to that for typical monoclonal antibodies
Seasoned and Well-rounded Management Team with Global Track Records
Dr. Chengbin Wu is a top expert in the BsAb area with a well-established track record
Team includes other industry veterans with complementary experiences from early discovery, clinical development, CMC, to business development and financing
EpimAb Aims to Redefine Bispecific Antibodies (BsAb)
undefined
EpimAb Milestone
2015
Cayman Islands Founded
Seed Financing completed
2016
Shanghai Company Founded
2017
Series A Financing completed
2018
EMB-01 China IND approval
EMB-01 FDA IND approval
2019
Series B Financing completed
The U.S. Patent on FIT-lg® granted
2021
EMB-06 Phase I/II INDs approval in US/ China/ Australia
Series C completed
2022
The Convertible Notes Financing completed
EMB-07 solid tumor IND approval in Australia
2023
An option and evaluation agreement with Almirall
EMB-01 Phase I/II study completed
EMB-07 lymhoma IND approval in Australia
EMB-07 China IND approval
2024
A research collaboration with Candid
A license agreement with Vignette Bio
EMB-06 Phase I study completed
EMB-01 China Phase Ib IND approval
EMB-06 China Phase Ib IND approval
2025
A license agreement with Juri Biosciences
EMB-07 FDA IND approval
EMB-01 Phase II IND approval
Join the dynamic team at EpimAb to maximize your potential
and explore cutting-edge science
Join us